Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;7(1):e007080.
doi: 10.1136/bmjgh-2021-007080.

The cost of illness for childhood clinical pneumonia and invasive pneumococcal disease in Nigeria

Affiliations

The cost of illness for childhood clinical pneumonia and invasive pneumococcal disease in Nigeria

Aishatu Lawal Adamu et al. BMJ Glob Health. 2022 Jan.

Abstract

Background: Pneumococcal disease contributes significantly to childhood morbidity and mortality and treatment is costly. Nigeria recently introduced the pneumococcal conjugate vaccine (PCV) to prevent pneumococcal disease. The aim of this study is to estimate health provider and household costs for the treatment of pneumococcal disease in children aged <5 years (U5s), and to assess the impact of these costs on household income.

Methods: We recruited U5s with clinical pneumonia, pneumococcal meningitis or pneumococcal septicaemia from a tertiary level hospital and a secondary level hospital in Kano, Nigeria. We obtained resource utilisation data from medical records to estimate costs of treatment to provider, and household expenses and income loss data from caregiver interviews to estimate costs of treatment to households. We defined catastrophic health expenditure (CHE) as household costs exceeding 25% of monthly household income and estimated the proportion of households that experienced it. We compared CHE across tertiles of household income (from the poorest to least poor).

Results: Of 480 participants recruited, 244 had outpatient pneumonia, and 236 were hospitalised with pneumonia (117), septicaemia (66) and meningitis (53). Median (IQR) provider costs were US$17 (US$14-22) for outpatients and US$272 (US$271-360) for inpatients. Median household cost was US$51 (US$40-69). Overall, 33% of households experienced CHE, while 53% and 4% of the poorest and least poor households, experienced CHE, respectively. The odds of CHE increased with admission at the secondary hospital, a diagnosis of meningitis or septicaemia, higher provider costs and caregiver having a non-salaried job.

Conclusion: Provider costs are substantial, and households incur treatment expenses that considerably impact on their income and this is particularly so for the poorest households. Sustaining the PCV programme and ensuring high and equitable coverage to lower disease burden will reduce the economic burden of pneumococcal disease to the healthcare provider and households.

Keywords: child health; health economics; pneumococcal disease; pneumonia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Distribution of proportions of households encountering catastrophic costs at different threshold values of cost as a fraction of household income by tertiles of household income level. Tertiles range from the poorest households (tertile 1) to the least poor (tertile 3).

References

    1. Wahl B, O'Brien KL, Greenbaum A, et al. . Burden of Streptococcus pneumoniae and Haemophilus influenzae type B disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018;6:e744–57. 10.1016/S2214-109X(18)30247-X - DOI - PMC - PubMed
    1. GBD 2015 Mortality and Causes of Death Collaborators . Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet 2016;388:1459–544. 10.1016/S0140-6736(16)31012-1 - DOI - PMC - PubMed
    1. O'Brien KL, Wolfson LJ, Watt JP, et al. . Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893–902. 10.1016/S0140-6736(09)61204-6 - DOI - PubMed
    1. Chen C, Cervero Liceras F, Flasche S, et al. . Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health 2019;7:e58–67. 10.1016/S2214-109X(18)30422-4 - DOI - PMC - PubMed
    1. Zhang S, Sammon PM, King I, et al. . Cost of management of severe pneumonia in young children: systematic analysis. J Glob Health 2016;6:010408. 10.7189/jogh.06.010408 - DOI - PMC - PubMed

Publication types